Gotham Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.8M | Buy |
17,787
+3,270
| +23% | +$1.07M | 0.03% | 621 |
|
|
2025
Q1 | $3.92M | Buy |
14,517
+3,593
| +33% | +$970K | 0.03% | 597 |
|
|
2024
Q4 | $2.57M | Sell |
10,924
-6,651
| -38% | -$1.57M | 0.02% | 660 |
|
|
2024
Q3 | $4.83M | Buy |
17,575
+4,338
| +33% | +$1.19M | 0.05% | 500 |
|
|
2024
Q2 | $3.22M | Buy |
13,237
+11,190
| +547% | +$2.72M | 0.04% | 553 |
|
|
2024
Q1 | $306K | Sell |
2,047
-8,762
| -81% | -$1.31M | ﹤0.01% | 1178 |
|
|
2023
Q4 | $2.07M | Buy |
10,809
+7,727
| +251% | +$1.48M | 0.04% | 592 |
|
|
2023
Q3 | $546K | Sell |
3,082
-775
| -20% | -$137K | 0.01% | 950 |
|
|
2023
Q2 | $733K | Sell |
3,857
-1,259
| -25% | -$239K | 0.02% | 858 |
|
|
2023
Q1 | $1.02M | Buy |
5,116
+1,730
| +51% | +$347K | 0.02% | 736 |
|
|
2022
Q4 | $805K | Buy |
3,386
+3
| +0.1% | +$713 | 0.02% | 754 |
|
|
2022
Q3 | $677K | Buy |
3,383
+277
| +9% | +$55.4K | 0.02% | 771 |
|
|
2022
Q2 | $453K | Buy |
3,106
+1,808
| +139% | +$264K | 0.01% | 813 |
|
|
2022
Q1 | $212K | Buy |
+1,298
| New | +$212K | 0.01% | 1065 |
|
|
2020
Q2 | – | Sell |
-4,464
| Closed | -$486K | – | 1054 |
|
|
2020
Q1 | $486K | Buy |
4,464
+1,544
| +53% | +$168K | 0.01% | 726 |
|
|
2019
Q4 | $336K | Buy |
+2,920
| New | +$336K | 0.01% | 912 |
|
|
2017
Q4 | – | Sell |
-2,499
| Closed | -$294K | – | 926 |
|
|
2017
Q3 | $294K | Sell |
2,499
-7,185
| -74% | -$845K | ﹤0.01% | 805 |
|
|
2017
Q2 | $772K | Buy |
+9,684
| New | +$772K | 0.01% | 679 |
|